PerkinElmer
check quantity

Annexin Vivo 750 Fluorescent Imaging Agent

Determine early stages of apoptosis with Annexin-Vivo 750.

You successfully added item(s) to your cart

For laboratory use only. This product is intended for animal research only and not for use in humans.

Part Number
List Price
Your Price
Quantity
NEV11053
797.00 USD
more
Buy Now

Please enter valid quantity

Please login to add favorites

NULL OR EMPTY CART

Detail Information

Annexin A5 (Annexin V) is a cellular protein in the annexin group. Annexin V is a probe commonly used to detect apoptotic cells by its ability to bind to phosphatidylserine, a marker of apoptosis when it is on the outer leaflet of the plasma membrane.

Annexin-Vivo 750, from PerkinElmer, is a targeted fluorescent imaging agent comprising this selective protein, Annexin A5 and a near-infrared (NIR) fluorochrome. This agent has been developed to enable in vivo visualization and quantification of the membrane-bound phospholipid, phosphotidylserine, exposed in the outer leaflet of the cell membrane lipid bilayer during the early stages of apoptosis.

Specifications

Fluorescent Agent Type Targeted
Optical Imaging Classification Fluorescence Imaging
Quantity in a Package Amount 1.0 Units
Shipping Condition Blue Ice
Therapeutic Area Atherosclerosis, Oncology/Cancer
Unit Size 1 Vial (10 doses)
Wave Length 750 nm
Resources, Events & More
  • All

Application Note

Imaging Hepatocellular Liver Injury using NIR-labeled Annexin V

Drug induced liver injury (DILI) is a major reason for late stage termination of drug discovery research projects, highlighting the importance of early integration of liver safety assessment in the drug development process. A technical approach for in vivo toxicology determination was developed using Acetaminophen (APAP), a commonly used over-the-counter analgesic and antipyretic drug, to induce acute hepatocellular liver injury.

PDF 3 MB

Flyer

Poster

Combined efficacy & toxicity imaging following acute 5-FU treatment of HT-29 tumor xenografts

Cancer chemotherapy can produce severe side effects such as suppression of immune function and damage to heart muscle, gastrointestinal tract, and liver. If serious enough, tissue injury can be a major reason for late stage termination of drug discovery research projects, so it is becoming more important to integrate safety/toxicology assessments earlier in the drug development process. There are a variety of traditional serum markers, tailored mechanistically to specific tissues, however there are no current non-invasive assessment tools that are capable of looking broadly at in situ biological changes in target and non-target tissue induced by chemical insult.

PDF 1 MB

Technical Note

Annexin-Vivo 750 (Protocol)

Protocol for Annexin-Vivo 750 In Vivo Fluorescent Imaging Agent

PDF 257 KB
Annexin-Vivo™ 750 (Data Sheet)

Annexin-Vivo™ 750 is a targeted fluorescence imaging agent comprising a selective protein, Annexin A5 and a near-infrared (NIR) fluorochrome. This agent has been developed to enable in vivo visualization and quantification of the membrane-bound phospholipid, phosphotidylserine, exposed in the outer leaflet of the cell membrane lipid bilayer during the early stages of apoptosis.

PDF 158 KB